PCSA (Processa Pharmaceuticals) Change In Receivables: $0.03 Mil (TTM As of Mar. 2026)

What is Processa Pharmaceuticals Change In Receivables?

Processa Pharmaceuticals PCSA +9.64% 28 Change In Receivables is $0.03 Mil as of Mar. 2026. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Processa Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2026 was $0.00 Mil. It means Processa Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

Processa Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2025 was $0.00 Mil. It means Processa Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

Processa Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Processa Pharmaceuticals's liquidation value for the three months ended in Mar. 2026 was $-0.29 Mil.

Processa Pharmaceuticals (NAS:PCSA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Processa Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Processa Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Processa Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.691	-	1.98	+	0.75 * 0	+	0.5 * 0
=	-0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Processa Pharmaceuticals Change In Receivables Related Terms

Processa Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for Processa Pharmaceuticals's Change In Receivables can be seen below:

Processa Pharmaceuticals Change In Receivables Chart

Processa Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Change In Receivables

Get a 7-Day Free Trial

0.01

0.07

0.00

Processa Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Change In Receivables	Get a 7-Day Free Trial															-0.03	0.03	0.00	0.00	0.00

28GF Score

Processa Pharmaceuticals Inc PCSA

Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Processa Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03 Mil.

Frequently Asked Questions Learn more about Change In Receivables →

What does a Change In Receivables of $0.03 Mil mean?

Processa Pharmaceuticals (PCSA) has a Change In Receivables of $0.03 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Processa Pharmaceuticals and its competitors.

Is Processa Pharmaceuticals' Change In Receivables too high?

Processa Pharmaceuticals' current Change In Receivables is $0.03 Mil. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Processa Pharmaceuticals' Change In Receivables compare to ELAB and MBIO?

Processa Pharmaceuticals' Change In Receivables of $0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Receivables for a Biotechnology company?

A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Receivables mean?

A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current Change In Receivables is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Processa Pharmaceuticals stock overvalued right now?

Processa Pharmaceuticals (PCSA) has a current Change In Receivables of $0.03 Mil. The current Change In Receivables is $0.03 Mil. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Receivables calculated?

Change In Receivables is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current Change In Receivables is $0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Processa Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ELAB MBIO DRMA LIMN TCRT GNPX MLEC CLGN CPMV ADIL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 601 21st Street, Suite 300, Vero Beach, FL, USA, 32960

Website https://www.processapharmaceuticals.com

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

28GF Score

Get the complete analysis for PCSA

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16

Price

View PCSA Analysis

See Change In Receivables data for all stocks →